FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163135882> ?p ?o ?g. }

• W2163135882 endingPage "1557" @default.
• W2163135882 startingPage "1552" @default.
• W2163135882 abstract "Thiazolidinediones are supposed to be the pharmacologic agents that more physiologically fight the insulin resistance, but a possible adverse effect may be a weight increase. The aim of the study was to test the efficacy and tolerability of sibutramine on the metabolic effect of pioglitazone in obese patients with type 2 diabetes mellitus. All enrolled patients were required to have been diagnosed as being diabetic for at least 6 months and did not have glycemic control with diet and oral hypoglycemic agents such as sulfonylureas or metformin, both to the maximum tolerated dose. After a run-in period in which the eligible patients took a fixed dose of pioglitazone (30 mg/d), the patients were randomized to receive also sibutramine (10 mg/d) or placebo for 6 months. We assessed body mass index, hemoglobin A(1c) (HbA(1c)), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), postprandial plasma insulin (PPI), lipid profile, lipoprotein parameters, and lipoprotein (a) at baseline and after 3 and 6 months. No body mass index change was observed after 3 and 6 months in the pioglitazone + placebo (pp) group. Significant decrease was present in the pioglitazone + sibutramine (ps) group after 3 (P < .05) and 6 months (P < .01) compared with the baseline values, and this variation was significant (P < .05) between groups. A significant HbA(1c) decrease was observed after 3 (P < .05) and 6 months (P < .01) in both groups with respect to the baseline values. There was no difference in HbA(1c) value between the 2 groups. No FPG, PPG, FPI, PPI, and homeostasis model assessment index change was observed at 3 months, whereas a significant decrease was present after 6 months (P < .05), in both groups with respect to the baseline values. There was no difference in FPG, PPG, FPI, PPI, and homeostasis model assessment index value between the pp and ps groups. No significant low-density lipoprotein cholesterol change was observed at 3 months, whereas a significant decrease was present after 6 months (P < .05), in both groups with respect to the baseline values. There was no difference in low-density lipoprotein cholesterol value between the pp and ps groups. No triglyceride variation was present at 3 and 6 months in the pp group and at 3 months in the ps group, whereas a significant decrease was observed at 6 months (P < .05) in the ps group with respect to the baseline values. There was no difference in triglyceride value between both groups. No high-density lipoprotein cholesterol, apolipoprotein A-I, apolipoprotein B, and lipoprotein (a) changes were present in both groups with respect to the baseline values. Sibutramine appears to be a tolerable and efficacious drug when added to pioglitazone for the global management of obese diabetic patients." @default.
• W2163135882 created "2016-06-24" @default.
• W2163135882 creator A5011551760 @default.
• W2163135882 creator A5021841408 @default.
• W2163135882 creator A5044628820 @default.
• W2163135882 creator A5049126629 @default.
• W2163135882 creator A5049217502 @default.
• W2163135882 creator A5050662641 @default.
• W2163135882 creator A5068440626 @default.
• W2163135882 creator A5085734415 @default.
• W2163135882 date "2008-11-01" @default.
• W2163135882 modified "2023-10-16" @default.
• W2163135882 title "Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone" @default.
• W2163135882 cites W1967818553 @default.
• W2163135882 cites W1971172093 @default.
• W2163135882 cites W1988492825 @default.
• W2163135882 cites W1991899069 @default.
• W2163135882 cites W2008497553 @default.
• W2163135882 cites W2021475323 @default.
• W2163135882 cites W2036169665 @default.
• W2163135882 cites W2041794872 @default.
• W2163135882 cites W2047108227 @default.
• W2163135882 cites W2063713206 @default.
• W2163135882 cites W2068361594 @default.
• W2163135882 cites W2070937608 @default.
• W2163135882 cites W2087880294 @default.
• W2163135882 cites W2090255610 @default.
• W2163135882 cites W2099767116 @default.
• W2163135882 cites W2116404316 @default.
• W2163135882 cites W2119754700 @default.
• W2163135882 cites W2120774442 @default.
• W2163135882 cites W2126603766 @default.
• W2163135882 cites W2131343538 @default.
• W2163135882 cites W2136592002 @default.
• W2163135882 cites W2160234571 @default.
• W2163135882 cites W2166095598 @default.
• W2163135882 cites W2317830946 @default.
• W2163135882 cites W2322658918 @default.
• W2163135882 cites W2325322971 @default.
• W2163135882 cites W4212842119 @default.
• W2163135882 cites W4239408478 @default.
• W2163135882 cites W57882500 @default.
• W2163135882 doi "https://doi.org/10.1016/j.metabol.2008.06.010" @default.
• W2163135882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18940393" @default.
• W2163135882 hasPublicationYear "2008" @default.
• W2163135882 type Work @default.
• W2163135882 sameAs 2163135882 @default.
• W2163135882 citedByCount "14" @default.
• W2163135882 countsByYear W21631358822012 @default.
• W2163135882 countsByYear W21631358822013 @default.
• W2163135882 countsByYear W21631358822016 @default.
• W2163135882 countsByYear W21631358822020 @default.
• W2163135882 countsByYear W21631358822021 @default.
• W2163135882 crossrefType "journal-article" @default.
• W2163135882 hasAuthorship W2163135882A5011551760 @default.
• W2163135882 hasAuthorship W2163135882A5021841408 @default.
• W2163135882 hasAuthorship W2163135882A5044628820 @default.
• W2163135882 hasAuthorship W2163135882A5049126629 @default.
• W2163135882 hasAuthorship W2163135882A5049217502 @default.
• W2163135882 hasAuthorship W2163135882A5050662641 @default.
• W2163135882 hasAuthorship W2163135882A5068440626 @default.
• W2163135882 hasAuthorship W2163135882A5085734415 @default.
• W2163135882 hasConcept C126322002 @default.
• W2163135882 hasConcept C134018914 @default.
• W2163135882 hasConcept C142724271 @default.
• W2163135882 hasConcept C197934379 @default.
• W2163135882 hasConcept C204787440 @default.
• W2163135882 hasConcept C27081682 @default.
• W2163135882 hasConcept C2777180221 @default.
• W2163135882 hasConcept C2777391703 @default.
• W2163135882 hasConcept C2777646958 @default.
• W2163135882 hasConcept C2778199505 @default.
• W2163135882 hasConcept C2778270857 @default.
• W2163135882 hasConcept C2778375690 @default.
• W2163135882 hasConcept C2778384471 @default.
• W2163135882 hasConcept C2779306644 @default.
• W2163135882 hasConcept C2780221984 @default.
• W2163135882 hasConcept C2780323712 @default.
• W2163135882 hasConcept C2780473172 @default.
• W2163135882 hasConcept C2910068830 @default.
• W2163135882 hasConcept C511355011 @default.
• W2163135882 hasConcept C544821477 @default.
• W2163135882 hasConcept C555293320 @default.
• W2163135882 hasConcept C71924100 @default.
• W2163135882 hasConcept C90924648 @default.
• W2163135882 hasConceptScore W2163135882C126322002 @default.
• W2163135882 hasConceptScore W2163135882C134018914 @default.
• W2163135882 hasConceptScore W2163135882C142724271 @default.
• W2163135882 hasConceptScore W2163135882C197934379 @default.
• W2163135882 hasConceptScore W2163135882C204787440 @default.
• W2163135882 hasConceptScore W2163135882C27081682 @default.
• W2163135882 hasConceptScore W2163135882C2777180221 @default.
• W2163135882 hasConceptScore W2163135882C2777391703 @default.
• W2163135882 hasConceptScore W2163135882C2777646958 @default.
• W2163135882 hasConceptScore W2163135882C2778199505 @default.
• W2163135882 hasConceptScore W2163135882C2778270857 @default.
• W2163135882 hasConceptScore W2163135882C2778375690 @default.
• W2163135882 hasConceptScore W2163135882C2778384471 @default.

• next